These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 23732371)

  • 61. Early low-dose rituximab for active thyroid eye disease: An effective and well-tolerated treatment.
    Insull EA; Sipkova Z; David J; Turner HE; Norris JH
    Clin Endocrinol (Oxf); 2019 Jul; 91(1):179-186. PubMed ID: 30864162
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Failure of rituximab treatment in a case of severe thyroid ophthalmopathy unresponsive to steroids.
    Krassas GE; Stafilidou A; Boboridis KG
    Clin Endocrinol (Oxf); 2010 Jun; 72(6):853-5. PubMed ID: 20039891
    [No Abstract]   [Full Text] [Related]  

  • 63. Periocular methotrexate versus periocular triamcinolone injections for active thyroid-associated orbitopathy: a randomized clinical trial.
    Swaify IY; Nasr HE; El Essawy RA; Elessawy KB
    Jpn J Ophthalmol; 2023 Nov; 67(6):699-710. PubMed ID: 37540324
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Machine learning-assisted system using digital facial images to predict the clinical activity score in thyroid-associated orbitopathy.
    Moon JH; Shin K; Lee GM; Park J; Lee MJ; Choung H; Kim N
    Sci Rep; 2022 Dec; 12(1):22085. PubMed ID: 36543834
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Observation study of using a small dose of rituximab treatment for thyroid-associated ophthalmopathy in seven Chinese patients: One pilot study.
    Wang Y; Hu H; Chen L; Zhang H; Yang T; Xu X; Chen H
    Front Endocrinol (Lausanne); 2022; 13():1079852. PubMed ID: 36743915
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [The importance of standardized periorbital steroid injections for thyroid-associated ophthalmopathy].
    Li DM; Jiang X
    Zhonghua Yan Ke Za Zhi; 2022 Sep; 58(9):641-645. PubMed ID: 36069084
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Rituximab in the Treatment of Thyroid Eye Disease: A Review.
    Ostrowski RA; Bussey MR; Shayesteh Y; Jay WM
    Neuroophthalmology; 2015 Jun; 39(3):109-115. PubMed ID: 27928343
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Teprotumumab (Tepezza) for thyroid eye disease.
    Med Lett Drugs Ther; 2021 May; 63(1625):87-88. PubMed ID: 34101720
    [No Abstract]   [Full Text] [Related]  

  • 69. Will biological agents supplant systemic glucocorticoids as the first-line treatment for thyroid-associated ophthalmopathy?
    Smith TJ; Bartalena L
    Eur J Endocrinol; 2019 Nov; 181(5):D27-D43. PubMed ID: 31370005
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Differentiated approach to the treatment of autoimmune ophthalmopathy].
    Mazurov VI; Sviatova LE; Danilichev VF; Cheremisin VM; Gurevich KIa
    Probl Endokrinol (Mosk); 1993; 39(1):24-7. PubMed ID: 8058657
    [TBL] [Abstract][Full Text] [Related]  

  • 71. [Ophthalmological signs in thyroid pathology: our experience].
    Carlesimo SC; Abdolrahimzadeh S; Di Santo L; Mazzeo F
    Clin Ter; 2012 Nov; 163(6):e397-400. PubMed ID: 23306752
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Fatal liver failure after high-dose glucocorticoid pulse therapy in a patient with severe thyroid eye disease.
    Weissel M; Hauff W
    Thyroid; 2000 Jun; 10(6):521. PubMed ID: 10907999
    [No Abstract]   [Full Text] [Related]  

  • 73. Research digest: topical trials in thyroid disease.
    Preiss D; Cleland S; Sattar N
    Lancet Diabetes Endocrinol; 2017 Jul; 5(7):497. PubMed ID: 28601582
    [No Abstract]   [Full Text] [Related]  

  • 74. Intravenous rituximab therapy for active Graves' ophthalmopathy: a meta-analysis.
    Chen J; Chen G; Sun H
    Hormones (Athens); 2021 Jun; 20(2):279-286. PubMed ID: 33783712
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Does rituximab improve clinical outcomes of patients with thyroid-associated ophthalmopathy? A systematic review and meta-analysis.
    Wang C; Ning Q; Jin K; Xie J; Ye J
    BMC Ophthalmol; 2018 Feb; 18(1):46. PubMed ID: 29452583
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Compressive Optic Neuropathy and Repeat Orbital Decompression: A Case Series.
    Kauh CY; Gupta S; Douglas RS; Elner VM; Nelson CC; Niziol LM; Kahana A
    Ophthalmic Plast Reconstr Surg; 2015; 31(5):385-90. PubMed ID: 25533274
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Treatment options for thyroid eye disease.
    Pillar AJ; Richa DC
    Curr Treat Options Neurol; 2014 Aug; 16(8):303. PubMed ID: 24928251
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Intraorbital injection of rituximab versus high dose of systemic glucocorticoids in the treatment of thyroid-associated orbitopathy.
    Savino G; Mandarà E; Gari M; Battendieri R; Corsello SM; Pontecorvi A
    Endocrine; 2015 Feb; 48(1):241-7. PubMed ID: 24880619
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Intraorbital injection of Rituximab in idiopathic orbital inflammatory syndrome: case reports.
    Savino G; Battendieri R; Siniscalco A; Mandarà E; Mulè A; Petrone G; Traina S; Riso M
    Rheumatol Int; 2015 Jan; 35(1):183-8. PubMed ID: 24879326
    [TBL] [Abstract][Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.